D. Addington, J. Addington, and E. Maticka-tyndale, Assessing Depression in Schizophrenia, Br J Psychiatry, vol.22, pp.39-44, 1993.

K. Ahn, M. Mckinney, and B. Cravatt, Enzymatic Pathways That Regulate Endocannabinoid Signaling in the Nervous System, Chemical reviews, 2008.

A. Aleman, R. Hijman, E. H. De-haan, and R. S. Kahn, Memory impairment in schizophrenia: a meta-analysis, Am J Psychiatry, vol.156, pp.1358-1366, 1999.

L. Altshuler, J. Ventura, W. Van-gorp, M. Green, D. Theberge et al., Neurocognitive function in clinically stable men with bipolar I disorder or schizophrenia and normal control subjects, Biological Psychiatry, vol.56, issue.8, pp.560-569, 2004.
DOI : 10.1016/j.biopsych.2004.08.002

N. C. Andreasen, The Scale for the Assessment of Negative Symptoms (SANS), Br J Psychiatry, vol.7, pp.49-58, 1989.

N. C. Andreasen, S. Arndt, D. Del-miller, M. ·. Flaum, and P. Napoulos, Correlational Studies of the Scale for the Assessment of Negative Symptoms and the Scale for the Assessment of Positive Symptoms: An Overview and Update, Psychopathology, vol.28, issue.1, pp.7-17, 1995.
DOI : 10.1159/000284894

S. Andréasson, P. Allebeck, A. Engström, and U. Rydberg, CANNABIS AND SCHIZOPHRENIA A Longitudinal Study of Swedish Conscripts, The Lancet, vol.330, issue.8574, pp.1483-1489, 1987.
DOI : 10.1016/S0140-6736(87)92620-1

L. Arseneault, M. Cannon, R. Poulton, R. Murray, A. Caspi et al., Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study, BMJ, vol.325, issue.7374, pp.1212-1213, 2002.
DOI : 10.1136/bmj.325.7374.1212

A. D. Baddeley and G. J. Hitch, Working memory): Recent advancs in learning and motivation, pp.47-90, 1974.

A. D. Baddeley, La mémoire humaine: théorie et pratique, 1993.

R. Benedict, . Schretlend, L. Groninger, and J. Brandt, Hopkins Verbal Learning Test ? Revised: Normative Data and Analysis of Inter-Form and Test-Retest Reliability, The Clinical Neuropsychologist (Neuropsychology, Development and Cognition: Section D), vol.12, issue.1, pp.43-55, 1998.
DOI : 10.1076/clin.12.1.43.1726

G. Berding, U. Schneider, P. Gielow, R. Buchert, F. Donnerstag et al., Feasibility of central cannabinoid CB1 receptor imaging with [124I]AM281 PET demonstrated in a schizophrenic patient, Psychiatry Research: Neuroimaging, vol.147, issue.2-3, pp.249-56, 2006.
DOI : 10.1016/j.pscychresns.2006.02.002

A. Best and W. Regehr, Serotonin Evokes Endocannabinoid Release and Retrogradely Suppresses Excitatory Synapses, Journal of Neuroscience, vol.28, issue.25, pp.6508-6523, 2008.
DOI : 10.1523/JNEUROSCI.0678-08.2008

S. Bhattacharyya, P. Morrison, P. Fusar-poli, R. Martin-santos, S. Borgwardt et al., Opposite Effects of ??-9-Tetrahydrocannabinol and Cannabidiol on Human Brain Function and Psychopathology, Neuropsychopharmacology, vol.20, issue.3, pp.764-74, 2010.
DOI : 10.1038/npp.2009.184

M. Bioque, B. Cabrera, B. García-bueno, K. Mac-dowell, C. Torrent et al., Dysregulated peripheral endocannabinoid system signaling is associated with cognitive deficits in first-episode psychosis, Journal of Psychiatric Research, vol.75, pp.14-21, 2016.
DOI : 10.1016/j.jpsychires.2016.01.002

T. Bisogno, L. Hanus, D. Petrocellis, L. Tchilibon, S. Ponde et al., Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide, British Journal of Pharmacology, vol.400, issue.4, pp.845-52, 2001.
DOI : 10.1038/sj.bjp.0704327

K. Böcker, C. Hunault, J. Gerritsen, M. Kruidenier, T. Mensinga et al., Cannabinoid Modulations of Resting State EEG Theta Power and Working Memory Are Correlated in Humans, Journal of Cognitive Neuroscience, vol.21, issue.9, pp.1906-1922, 2010.
DOI : 10.1126/science.1060496

D. Boggs, D. Kelly, R. Mcmahon, J. Gold, D. Gorelick et al., Rimonabant for neurocognition in schizophrenia: A 16-week double blind randomized placebo controlled trial, Schizophrenia Research, vol.134, issue.2-3, pp.207-217, 2012.
DOI : 10.1016/j.schres.2011.11.009

E. Bora and R. Murray, Meta-analysis of Cognitive Deficits in Ultra-high Risk to Psychosis and First-Episode Psychosis: Do the Cognitive Deficits Progress Over, or After, the Onset of Psychosis?, Schizophrenia Bulletin, vol.40, issue.4, pp.744-55, 2014.
DOI : 10.1093/schbul/sbt085

M. Bossong, G. Jager, S. Bhattacharyya, and P. Allen, Acute and Non-acute Effects of Cannabis on Human Memory Function: A Critical Review of Neuroimaging Studies, Current Pharmaceutical Design, vol.20, issue.13, pp.2114-2139, 2014.
DOI : 10.2174/13816128113199990436

M. Bossong, J. Jansma, S. Bhattacharyya, and N. Ramsey, Role of the endocannabinoid system in brain functions relevant for schizophrenia: An overview of human challenge studies with cannabis or ???9-tetrahydrocannabinol (THC), Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol.52, pp.53-69, 2014.
DOI : 10.1016/j.pnpbp.2013.11.017

M. Bossong, J. Jansma, H. Van-hell, G. Jager, R. Kahn et al., Default Mode Network in the Effects of ??9-Tetrahydrocannabinol (THC) on Human Executive Function, PLoS ONE, vol.25, issue.7, p.70074, 2013.
DOI : 10.1371/journal.pone.0070074.s004

S. Botero, C. Muñoz, M. Ocampo, M. Escobar, A. Rangel et al., Verbal Working Memory in Individuals with Schizophrenia and Their First Degree Relatives, Actas Esp Psiquiatr, vol.41, pp.106-120, 2013.

J. Brown, S. Horváth, K. Garbett, M. Schmidt, M. Everheart et al., The role of cannabinoid 1 receptor expressing interneurons in behavior, Neurobiology of Disease, vol.63, pp.210-231, 2014.
DOI : 10.1016/j.nbd.2013.11.001

S. Brown, S. Brenowitz, and W. Regehr, Brief presynaptic bursts evoke synapse-specific retrograde inhibition mediated by endogenous cannabinoids, Nature Neuroscience, vol.6, issue.10, pp.1048-57, 2003.
DOI : 10.1038/nn1126

T. Cannon, T. Gasperoni, T. Van-erp, and I. Rosso, Quantitative neural indicators of liability to schizophrenia: Implications for molecular genetic studies, American Journal of Medical Genetics, vol.157, issue.1, pp.16-25, 2001.
DOI : 10.1002/1096-8628(20010108)105:1<16::AID-AJMG1046>3.0.CO;2-Z

M. Caterina and J. D. , : A Molecular Gateway to the Pain Pathway, Annual Review of Neuroscience, vol.24, issue.1, pp.487-517, 2001.
DOI : 10.1146/annurev.neuro.24.1.487

J. Ceccarini, Increased ventral striatal CB1 receptor binding is related to negative symptoms in drug-free patients with schizophrenia, NeuroImage, vol.79, pp.129-159, 2014.
DOI : 10.1016/j.neuroimage.2013.04.052

D. Centonze, L. Battistini, and M. Maccarrone, The Endocannabinoid System in Peripheral Lymphocytes as a Mirror of Neuroinflammatory Diseases, Current Pharmaceutical Design, vol.14, issue.23, pp.2370-2412, 2008.
DOI : 10.2174/138161208785740018

R. Chan, E. Chen, and C. Law, Specific executive dysfunction in patients with first-episode medication-na??ve schizophrenia, Schizophrenia Research, vol.82, issue.1, pp.51-64, 2006.
DOI : 10.1016/j.schres.2005.09.020

N. Charrier, K. Chevreul, and I. Durand-zaleski, Le coût de la schizophrénie, 2009.

I. Chavarría-siles, J. Contreras-rojas, E. Hare, C. Walss-bass, P. Quezada et al., Cannabinoid receptor 1 gene (CNR1) and susceptibility to a quantitative phenotype for hebephrenic schizophrenia, American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, vol.21, issue.3, pp.279-84, 2008.
DOI : 10.1002/ajmg.b.30592

A. Chávez, C. Chiu, and P. Castillo, TRPV1 activation by endogenous anandamide triggers postsynaptic long-term depression in dentate gyrus, Nature Neuroscience, vol.22, issue.12, pp.1511-1519, 2010.
DOI : 10.1523/JNEUROSCI.4433-07.2007

K. Chen, A. Ratzliff, L. Hilgenberg, A. Gulyás, T. Freund et al., Long-Term Plasticity of Endocannabinoid Signaling Induced by Developmental Febrile Seizures, Neuron, vol.39, issue.4, pp.599-611, 2003.
DOI : 10.1016/S0896-6273(03)00499-9

W. Chen and S. Faraone, Sustained attention deficits as markers of genetic susceptibility to schizophrenia, American Journal of Medical Genetics, vol.38, issue.1, pp.52-59, 2000.
DOI : 10.1002/(SICI)1096-8628(200021)97:1<52::AID-AJMG7>3.0.CO;2-6

M. Cohen, N. Solowij, and V. Carr, Cannabis, Cannabinoids and Schizophrenia: Integration of the Evidence, Australian & New Zealand Journal of Psychiatry, vol.28, issue.5, pp.357-68, 2008.
DOI : 10.1016/S0140-6736(07)61162-3

N. Cohen and L. Squire, Preserved learning and retention of pattern-analyzing skill in amnesia: dissociation of knowing how and knowing that, Science, vol.210, issue.4466, pp.207-217, 1980.
DOI : 10.1126/science.7414331

B. Cornblatt and J. Keilp, Impaired Attention, Genetics, and the Pathophysiology of Schizophrenia, Schizophrenia Bulletin, vol.20, issue.1, pp.31-46, 1994.
DOI : 10.1093/schbul/20.1.31

M. Costa, A. Squassina, D. Congiu, C. Chillotti, P. Niola et al., Investigation of endocannabinoid system genes suggests association between peroxisome proliferator activator receptor-?? gene (PPARA) and schizophrenia, European Neuropsychopharmacology, vol.23, issue.7, pp.749-759, 2013.
DOI : 10.1016/j.euroneuro.2012.07.007

V. Dalton, L. Long, S. Weickert, C. Zavitsanou, and K. , Paranoid Schizophrenia is Characterized by Increased CB1 Receptor Binding in the Dorsolateral Prefrontal Cortex, Neuropsychopharmacology, vol.56, issue.8, pp.1620-1630, 2011.
DOI : 10.1590/S0100-879X2006000400001

J. M. Danion, C. Cuervo, P. Piolino, C. Huron, M. Riutort et al., Conscious recollection in autobiographical memory: An investigation in schizophrenia, Consciousness and Cognition, vol.14, issue.3, pp.535-547, 2005.
DOI : 10.1016/j.concog.2005.01.005

URL : https://hal.archives-ouvertes.fr/hal-00314809

J. Danion, C. Huron, P. Vidailhet, and F. Berna, Functional Mechanisms of Episodic Memory Impairment in Schizophrenia, The Canadian Journal of Psychiatry, vol.13, issue.2, pp.693-701, 2007.
DOI : 10.1177/070674370705201103

J. Danion, T. Meulemans, F. Kauffmann-muller, and H. Vermaat, Intact Implicit Learning in Schizophrenia, American Journal of Psychiatry, vol.158, issue.6, pp.944-952, 2001.
DOI : 10.1176/appi.ajp.158.6.944

J. Danion, L. Rizzo, and A. Bruant, Functional Mechanisms Underlying Impaired Recognition Memory and Conscious Awareness in Patients With Schizophrenia, Archives of General Psychiatry, vol.56, issue.7, pp.639-683, 1999.
DOI : 10.1001/archpsyc.56.7.639

D. Marchi, N. , D. Petrocellis, L. Orlando, P. Daniele et al., Endocannabinoid Signalling in the Blood of Patients with Schizophrenia, Lipids Health Dis, vol.19, pp.2-5, 2003.

D. Petrocellis, L. Ligresti, A. Moriello, A. Allarà, M. Bisogno et al., extracts on TRP channels and endocannabinoid metabolic enzymes, British Journal of Pharmacology, vol.333, issue.7, pp.1479-94, 2011.
DOI : 10.1111/j.1476-5381.2010.01166.x

B. Dean, S. Sundram, R. Bradbury, E. Scarr, and D. Copolov, Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use, Neuroscience, vol.103, issue.1, pp.9-15, 2001.
DOI : 10.1016/S0306-4522(00)00552-2

D. Forti, M. Iyegbe, C. Sallis, H. Kolliakou, A. Falcone et al., Confirmation that the AKT1 (rs2494732) Genotype Influences the Risk of Psychosis in Cannabis Users, Biological Psychiatry, vol.72, issue.10, pp.811-817, 2012.
DOI : 10.1016/j.biopsych.2012.06.020

D. Forti, M. Morgan, C. Dazzan, P. Pariante, C. Mondelli et al., High-potency cannabis and the risk of psychosis, The British Journal of Psychiatry, vol.195, issue.6, pp.488-91, 2009.
DOI : 10.1192/bjp.bp.109.064220

D. Forti, M. Sallis, H. Allegri, F. Trotta, A. Ferraro et al., Daily Use, Especially of High-Potency Cannabis, Drives the Earlier Onset of Psychosis in Cannabis Users, Schizophrenia Bulletin, vol.40, issue.6, pp.1509-1526, 2014.
DOI : 10.1093/schbul/sbt181

D. Marzo, V. , D. Petrocellis, L. Fezza, F. Ligresti et al., Anandamide receptors, Prostaglandins, Leukotrienes and Essential Fatty Acids (PLEFA), vol.66, issue.2-3, pp.377-91, 2002.
DOI : 10.1054/plef.2001.0349

D. Marzo, V. Maccarrone, M. , and A. , FAAH and anandamide: is 2-AG really the odd one out?, Trends in Pharmacological Sciences, vol.29, issue.5, pp.229-262, 2008.
DOI : 10.1016/j.tips.2008.03.001

I. Dinu, S. Popa, M. Bîcu, E. Mo?a, and M. Mo?a, The Implication of CNR1 Gene's Polymorphisms in the Modulation of Endocannabinoid System Effects, Rom J Intern Med, vol.47, pp.9-18, 2009.

O. Doughty and D. Done, Is semantic memory impaired in schizophrenia? A systematic review and meta-analysis of 91 studies, Cognitive Neuropsychiatry, vol.23, issue.6, pp.473-509, 2009.
DOI : 10.1016/j.psychres.2003.07.009

M. Egan, T. Goldberg, T. Gscheidle, M. Weirich, L. Bigelow et al., Relative Risk of Attention Deficits in Siblings of Patients With Schizophrenia, American Journal of Psychiatry, vol.157, issue.8, pp.1309-1325, 2000.
DOI : 10.1176/appi.ajp.157.8.1309

S. Eggan, T. Hashimoto, and D. Lewis, Reduced Cortical Cannabinoid 1 Receptor Messenger RNA and Protein Expression in Schizophrenia, Archives of General Psychiatry, vol.65, issue.7, pp.772-84, 2008.
DOI : 10.1001/archpsyc.65.7.772

S. Eggan, M. Lazarus, S. Stoyak, D. Volk, J. Glausier et al., Cortical Glutamic Acid Decarboxylase 67 Deficiency Results in Lower Cannabinoid 1 Receptor Messenger RNA Expression: Implications for Schizophrenia, Biological Psychiatry, vol.71, issue.2, pp.114-123, 2012.
DOI : 10.1016/j.biopsych.2011.09.014

C. Ehlers, W. Slutske, P. Lind, and K. Wilhelmsen, Abstract, Twin Research and Human Genetics, vol.32, issue.06, pp.805-816, 2007.
DOI : 10.1074/jbc.M504942200

B. Elvevåg, T. Weickert, M. Wechsler, R. Coppola, D. Weinberger et al., An investigation of the integrity of semantic boundaries in schizophrenia, Schizophrenia Research, vol.53, issue.3, pp.187-98, 2002.
DOI : 10.1016/S0920-9964(01)00202-X

A. Englund, P. Morrison, J. Nottage, D. Hague, F. Kane et al., Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment, Journal of Psychopharmacology, vol.32, issue.1, pp.19-27, 2013.
DOI : 10.1007/BF00432554

F. Eustache and B. Desgranges, Vers un modèle unifié de la mémoire, Cerveau&psycho, vol.28, pp.1-9, 2008.

A. Feinstein, T. Goldberg, B. Nowlin, and D. Weinberger, Types and characteristics of remote memory impairment in schizophrenia, Schizophrenia Research, vol.30, issue.2, pp.155-63, 1998.
DOI : 10.1016/S0920-9964(97)00129-1

B. Ferrer, N. Asbrock, S. Kathuria, D. Piomelli, and A. Giuffrida, Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesias, European Journal of Neuroscience, vol.4, issue.6, pp.1607-1621, 2003.
DOI : 10.1016/S0304-3940(99)00762-4

R. Ferretjans, S. De-campos, R. Ribeiro-santos, F. Guimarães, K. De-oliveira et al., Cognitive performance and peripheral endocannabinoid system receptor expression in schizophrenia, Schizophrenia Research, vol.156, issue.2-3, pp.254-60, 2014.
DOI : 10.1016/j.schres.2014.04.028

B. Feve, Antagonistes Des Récepteurs CB1 Des Endocannabinoïdes : Quels Arguments Pour Des Effets Favorables Indépendants de La Seule Réduction Pondérale ?, Métabolismes Hormones Diabètes et Nutrition, pp.109-115, 2008.

M. Fioravanti, V. Bianchi, and M. Cinti, Cognitive deficits in schizophrenia: an updated metanalysis of the scientific evidence, BMC Psychiatry, vol.64, issue.Suppl 2, p.64, 2012.
DOI : 10.1037/0022-006X.64.5.973

M. Fioravanti, O. Carlone, B. Vitale, M. Cinti, and C. L. , A Meta-Analysis of Cognitive Deficits in Adults with a Diagnosis of Schizophrenia, Neuropsychology Review, vol.108, issue.1, pp.73-95, 2005.
DOI : 10.1007/s11065-005-6254-9

N. Forbes, L. Carrick, A. Mcintosh, and S. Lawrie, Working memory in schizophrenia: a meta-analysis, Psychological Medicine, vol.22, issue.06, pp.889-905, 2009.
DOI : 10.1097/00005053-200210000-00004

D. Freeman, K. Pugh, C. Green, L. Valmaggia, G. Dunn et al., A Measure of State Persecutory Ideation for Experimental Studies, The Journal of Nervous and Mental Disease, vol.195, issue.9, pp.781-785, 2007.
DOI : 10.1097/NMD.0b013e318145a0a9

C. Frith, The Cognitive Neuropsychology of Schizophrenia, Essays in Cognitive Neuropsychology, 2008.

G. Gerdeman, J. Ronesi, and D. Lovinger, Postsynaptic endocannabinoid release is critical to long-term depression in the striatum, Nature Neuroscience, vol.5, pp.446-51, 2002.
DOI : 10.1038/nn832

A. Giuffrida, F. Leweke, C. Gerth, D. Schreiber, D. Koethe et al., Cerebrospinal Anandamide Levels are Elevated in Acute Schizophrenia and are Inversely Correlated with Psychotic Symptoms, Neuropsychopharmacology, vol.29, issue.11, pp.2108-2122, 2004.
DOI : 10.1038/sj.npp.1300558

A. Giuffrida, L. Parsons, T. Kerr, R. De-fonseca, F. Navarro et al., Dopamine Activation of Endogenous Cannabinoid Signaling in Dorsal Striatum, Nat Neurosci, vol.2, pp.358-63, 1999.

A. Gladkevich, H. Kauffman, and J. Korf, Lymphocytes as a neural probe: potential for studying psychiatric disorders, Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol.28, issue.3, pp.559-76, 2004.
DOI : 10.1016/j.pnpbp.2004.01.009

J. Gold, C. Randolph, C. Carpenter, T. Goldberg, and D. Weinberger, Forms of memory failure in schizophrenia., Journal of Abnormal Psychology, vol.101, issue.3, pp.487-94, 1992.
DOI : 10.1037/0021-843X.101.3.487

P. Goldman-rakic, Working Memory Dysfunction in Schizophrenia, J Neuropsychiatry Clin Neurosci, vol.6, pp.348-57, 1994.

D. Gooding and K. Tallent, Nonverbal working memory deficits in schizophrenia patients: Evidence of a supramodal executive processing deficit, Schizophrenia Research, vol.68, issue.2-3, pp.189-201, 2004.
DOI : 10.1016/j.schres.2003.07.007

B. Grueter, G. Brasnjo, and R. Malenka, Postsynaptic TRPV1 triggers cell type???specific long-term depression in the nucleus accumbens, Nature Neuroscience, vol.21, issue.12, pp.1519-1544, 2010.
DOI : 10.1523/JNEUROSCI.0170-06.2006

W. Guy, Clinical Global Impression (CGI) ECDEU Assessment Manual for Psychopharmacology, 1976.

S. Haj-dahmane and R. Shen, The Wake-Promoting Peptide Orexin-B Inhibits Glutamatergic Transmission to Dorsal Raphe Nucleus Serotonin Neurons through Retrograde Endocannabinoid Signaling, Journal of Neuroscience, vol.25, issue.4, pp.896-905, 2005.
DOI : 10.1523/JNEUROSCI.3258-04.2005

J. Hallak, J. Machado-de-sousa, J. Crippa, R. Sanches, C. Trzesniak et al., Performance of schizophrenic patients in the Stroop Color Word Test and electrodermal responsiveness after acute administration of cannabidiol (CBD), Revista Brasileira de Psiquiatria, vol.32, issue.1, pp.56-61, 2010.
DOI : 10.1590/S1516-44462010000100011

P. Harvey, B. Palmer, R. Heaton, M. S. Kennedy, J. Brickman et al., Stability of Cognitive Performance in Older Patients With Schizophrenia: An 8-Week Test-Retest Study, American Journal of Psychiatry, vol.162, issue.1, pp.110-117, 2005.
DOI : 10.1176/appi.ajp.162.1.110

Y. Hashimotodani, T. Ohno-shosaku, and M. Kano, Ca2+-assisted receptor-driven endocannabinoid release: mechanisms that associate presynaptic and postsynaptic activities, Current Opinion in Neurobiology, vol.17, issue.3, pp.360-365, 2007.
DOI : 10.1016/j.conb.2007.03.012

R. Heaton, J. Gladsjo, B. Palmer, J. Kuck, T. Marcotte et al., Stability and Course of Neuropsychological Deficits in Schizophrenia, Archives of General Psychiatry, vol.58, issue.1, pp.24-32, 2001.
DOI : 10.1001/archpsyc.58.1.24

B. Heifets and P. Castillo, Endocannabinoid Signaling and Long-Term Synaptic Plasticity, Annual Review of Physiology, vol.71, issue.1, pp.283-306, 2009.
DOI : 10.1146/annurev.physiol.010908.163149

R. Heinrichs and K. Zakzanis, Neurocognitive deficit in schizophrenia: A quantitative review of the evidence., Neuropsychology, vol.12, issue.3, pp.426-471, 1998.
DOI : 10.1037/0894-4105.12.3.426

M. Herkenham, Cannabinoid receptor localization in brain., Proceedings of the National Academy of Sciences, vol.87, issue.5, pp.19-32, 1992.
DOI : 10.1073/pnas.87.5.1932

C. Hillard, K. Weinlander, and K. Stuhr, Contributions of endocannabinoid signaling to psychiatric disorders in humans: genetic and biochemical evidence, Neuroscience, vol.204, pp.207-236, 2012.
DOI : 10.1016/j.neuroscience.2011.11.020

M. Hirasawa, Y. Schwab, S. Natah, C. Hillard, K. Mackie et al., Dendritically released transmitters cooperate via autocrine and retrograde actions to inhibit afferent excitation in rat brain, The Journal of Physiology, vol.410, issue.2, pp.611-635, 2004.
DOI : 10.1113/jphysiol.2004.066159

J. Hirvonen, P. Zanotti-fregonara, J. Umhau, D. George, D. Rallis-frutos et al., Reduced cannabinoid CB1 receptor binding in alcohol dependence measured with positron emission tomography, Molecular Psychiatry, vol.45, issue.8, pp.916-937, 2013.
DOI : 10.1371/journal.pone.0023690

A. Hofer, E. Weiss, S. Golaszewski, C. Siedentopf, C. Brinkhoff et al., An fMRI Study of Episodic Encoding and Recognition of Words in Patients With Schizophrenia in Remission, American Journal of Psychiatry, vol.160, issue.5, pp.911-919, 2003.
DOI : 10.1176/appi.ajp.160.5.911

A. Hoff, C. Svetina, G. Shields, J. Stewart, and L. Delisi, Ten year longitudinal study of neuropsychological functioning subsequent to a first episode of schizophrenia, Schizophrenia Research, vol.78, issue.1, pp.27-34, 2005.
DOI : 10.1016/j.schres.2005.05.010

S. Hutton, B. Puri, L. Duncan, T. Robbins, T. Barnes et al., Executive function in first-episode schizophrenia, Psychological Medicine, vol.28, issue.2, pp.463-73, 1998.
DOI : 10.1017/S0033291797006041

A. Ilan, M. Smith, and A. Gevins, Effects of marijuana on neurophysiological signals of working and episodic memory, Psychopharmacology, vol.38, issue.2, pp.214-236, 2004.
DOI : 10.1007/s00213-004-1868-9

T. Iseger and M. Bossong, A systematic review of the antipsychotic properties of cannabidiol in humans, Schizophrenia Research, vol.162, issue.1-3, pp.153-61, 2015.
DOI : 10.1016/j.schres.2015.01.033

T. Jahn, G. Pitschel-walz, A. Gsottschneider, T. Froböse, S. Kraemer et al., Neurocognitive prediction of illness knowledge after psychoeducation in schizophrenia: results from the Munich COGPIP study, Psychological Medicine, vol.30, issue.03, pp.533-577, 2011.
DOI : 10.1093/schbul/sbl072

C. Jahshan, R. Heaton, S. Golshan, and K. Cadenhead, Course of neurocognitive deficits in the prodrome and first episode of schizophrenia., Neuropsychology, vol.24, issue.1, pp.109-129, 2010.
DOI : 10.1037/a0016791

K. Jenko, J. Hirvonen, I. Henter, K. Anderson, S. Zoghbi et al., Binding of a tritiated inverse agonist to cannabinoid CB1 receptors is increased in patients with schizophrenia, Schizophrenia Research, vol.141, issue.2-3, pp.185-193, 2012.
DOI : 10.1016/j.schres.2012.07.021

J. Desfossés, Étude Du Système Endocannabinoïde et Ses Implications Dans La Schizophrénie

S. Jones, G. Thornicroft, M. Coffey, and G. Dunn, A brief mental health outcome scale-reliability and validity of the Global Assessment of Functioning (GAF), The British Journal of Psychiatry, vol.166, issue.5, pp.654-663, 1995.
DOI : 10.1192/bjp.166.5.654

E. Joyce, S. Collinson, and P. Crichton, Verbal fluency in schizophrenia: relationship with executive function, semantic memory and clinical alogia, Psychological Medicine, vol.4, issue.01, pp.39-49, 1996.
DOI : 10.1016/0028-3932(90)90137-D

M. Kano, Control of synaptic function by endocannabinoid-mediated retrograde signaling, Proceedings of the Japan Academy, Series B, vol.90, issue.7, pp.235-50, 2014.
DOI : 10.2183/pjab.90.235

I. Katona, G. Urbán, M. Wallace, C. Ledent, K. Jung et al., Molecular Composition of the Endocannabinoid System at Glutamatergic Synapses, Journal of Neuroscience, vol.26, issue.21, pp.5628-5665, 2006.
DOI : 10.1523/JNEUROSCI.0309-06.2006

S. R. Kay, A. Fiszbein, and L. A. Opler, The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia, Schizophrenia Bulletin, vol.13, issue.2, pp.261-276, 1987.
DOI : 10.1093/schbul/13.2.261

G. Khandaker, J. Barnett, I. White, and P. Jones, A quantitative meta-analysis of population-based studies of premorbid intelligence and schizophrenia, Schizophrenia Research, vol.132, issue.2-3, pp.220-227, 2011.
DOI : 10.1016/j.schres.2011.06.017

J. Kim, M. Isokawa, C. Ledent, and B. Alger, Activation of Muscarinic Acetylcholine Receptors Enhances the Release of Endogenous Cannabinoids in the Hippocampus, J Neurosci, vol.22, pp.10182-91, 2002.

K. Kim, J. Park, D. Song, H. Koo, and S. An, Neurocognitive performance in subjects at ultrahigh risk for schizophrenia: a comparison with first-episode schizophrenia, Comprehensive Psychiatry, vol.52, issue.1, pp.33-40, 2011.
DOI : 10.1016/j.comppsych.2010.04.010

D. Koethe, A. Giuffrida, D. Schreiber, M. Hellmich, F. Schultze-lutter et al., Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis, The British Journal of Psychiatry, vol.194, issue.4, pp.371-373, 2009.
DOI : 10.1192/bjp.bp.108.053843

B. Kovasznay, J. Fleischer, M. Tanenberg-karant, L. Jandorf, A. Miller et al., Substance Use Disorder and the Early Course of Illness in Schizophrenia and Affective Psychosis, Schizophrenia Bulletin, vol.23, issue.2, pp.195-201, 1997.
DOI : 10.1093/schbul/23.2.195

M. Krebs, Y. Morvan, T. Jay, R. Gaillard, and O. Kebir, Psychotomimetic effects at initiation of cannabis use are associated with cannabinoid receptor 1 (CNR1) variants in healthy students, Molecular Psychiatry, vol.19, issue.4, pp.402-405, 2014.
DOI : 10.1074/jbc.M111.336750

URL : https://hal.archives-ouvertes.fr/hal-01312815

M. Lazenka, D. Selley, and L. Sim-selley, Brain regional differences in CB1 receptor adaptation and regulation of transcription, Life Sciences, vol.92, issue.8-9, pp.446-52, 2013.
DOI : 10.1016/j.lfs.2012.08.023

L. Roy and V. , Le problème du Binding ou de l'intégration des informations dans la schizophrénie, Neuropsychologie clinique de la schizophrénie, pp.23-54, 2011.

J. Lee and S. Park, Working Memory Impairments in Schizophrenia: A Meta-Analysis., Journal of Abnormal Psychology, vol.114, issue.4, pp.599-611, 2005.
DOI : 10.1037/0021-843X.114.4.599

E. Leiderman and S. Strejilevich, Visuospatial deficits in schizophrenia: central executive and memory subsystems impairments, Schizophrenia Research, vol.68, issue.2-3, pp.217-240, 2004.
DOI : 10.1016/S0920-9964(03)00215-9

T. Lerner and A. Kreitzer, RGS4 Is Required for Dopaminergic Control of Striatal LTD and Susceptibility to Parkinsonian Motor Deficits, Neuron, vol.73, issue.2, pp.347-59, 2012.
DOI : 10.1016/j.neuron.2011.11.015

F. Leweke, A. Giuffrida, D. Koethe, D. Schreiber, B. Nolden et al., Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: Impact of cannabis use, Schizophrenia Research, vol.94, issue.1-3, pp.29-36, 2007.
DOI : 10.1016/j.schres.2007.04.025

F. Leweke, A. Giuffrida, U. Wurster, H. Emrich, and D. Piomelli, Elevated endogenous cannabinoids in schizophrenia, NeuroReport, vol.10, issue.8, pp.1665-1674, 1999.
DOI : 10.1097/00001756-199906030-00008

F. Leweke, D. Piomelli, F. Pahlisch, D. Muhl, C. Gerth et al., Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia, Translational Psychiatry, vol.152, issue.3, 2012.
DOI : 10.1038/tp.2012.15

C. Lewis, D. Levinson, L. Wise, L. Delisi, R. Straub et al., Genome Scan Meta-Analysis of Schizophrenia and Bipolar Disorder, Part II: Schizophrenia, The American Journal of Human Genetics, vol.73, issue.1, pp.34-48, 2003.
DOI : 10.1086/376549

D. Linszen, P. Dingemans, and M. Lenior, Cannabis Abuse and the Course of Recent-Onset Schizophrenic Disorders, Archives of General Psychiatry, vol.51, issue.4, pp.273-282, 1994.
DOI : 10.1001/archpsyc.1994.03950040017002

M. Maccarrone, S. Rossi, M. Bari, D. Chiara, V. Fezza et al., Anandamide inhibits metabolism and physiological actions of 2-arachidonoylglycerol in the striatum, Nature Neuroscience, vol.294, issue.2, pp.152-161, 2008.
DOI : 10.1038/nn2042

T. Maejima, K. Hashimoto, T. Yoshida, A. Aiba, and M. Kano, Presynaptic Inhibition Caused by Retrograde Signal from Metabotropic Glutamate to Cannabinoid Receptors, Neuron, vol.31, issue.3, pp.463-75, 2001.
DOI : 10.1016/S0896-6273(01)00375-0

T. Maejima, S. Oka, Y. Hashimotodani, T. Ohno-shosaku, A. Aiba et al., Synaptically Driven Endocannabinoid Release Requires Ca2+-Assisted Metabotropic Glutamate Receptor Subtype 1 to Phospholipase C ??4 Signaling Cascade in the Cerebellum, Journal of Neuroscience, vol.25, issue.29, pp.6826-6861, 2005.
DOI : 10.1523/JNEUROSCI.0945-05.2005

P. Marcezewski, M. Van-der-linden, and F. Laroi, Further investigation of the Supervisory Attentional System in schizophrenia: Planning, inhibition, and rule abstraction, Cognitive Neuropsychiatry, vol.10, issue.3, pp.175-192, 2001.
DOI : 10.1192/bjp.172.2.142

G. Marsicano, C. Wotjak, S. Azad, T. Bisogno, G. Rammes et al., The endogenous cannabinoid system controls extinction of aversive memories, Nature, vol.19, issue.6897, pp.530-534, 2002.
DOI : 10.1016/S0306-4522(01)00336-0

I. Martínez-gras, J. Hoenicka, G. Ponce, R. Rodríguez-jiménez, M. Jiménez-arriero et al., (AAT)n repeat in the cannabinoid receptor gene, CNR1: association with schizophrenia in a Spanish population, AAT)n Repeat in the Cannabinoid Receptor Gene, CNR1, pp.437-478, 2006.
DOI : 10.1007/s00406-006-0665-3

P. Mckenna, D. Tamlyn, C. Lund, A. Mortimer, S. Hammond et al., Amnesic syndrome in schizophrenia, Psychological Medicine, vol.18, issue.04, pp.967-72, 1990.
DOI : 10.1192/bjp.136.4.384

T. Miller, T. Mcglashan, S. Woods, K. Stein, N. Driesen et al., Symptom assessment in schizophrenic prodromal states From Revolution to Evolution, Psychiatr Q. Moghaddam B, Javitt D Neuropsychopharmacology, vol.70, issue.37, pp.273-87, 1999.

C. Morgan and H. Curran, Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis, The British Journal of Psychiatry, vol.192, issue.4, pp.306-313, 2008.
DOI : 10.1192/bjp.bp.107.046649

C. Morgan, C. Gardener, G. Schafer, S. Swan, C. Demarchi et al., Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being, Psychological Medicine, vol.10, issue.02, pp.391-400, 2012.
DOI : 10.1192/bjp.bp.109.064220

C. Morgan, G. Schafer, T. Freeman, and H. Curran, Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study, The British Journal of Psychiatry, vol.197, issue.4, pp.285-90, 2010.
DOI : 10.1192/bjp.bp.110.077503

S. Moritz, M. Lambert, B. Andresen, A. Böthern, D. Naber et al., Subjective cognitive dysfunction in first-episode and chronic schizophrenic patients, Comprehensive Psychiatry, vol.42, issue.3, pp.213-219, 2001.
DOI : 10.1053/comp.2001.23144

R. Morris, T. Rushe, P. Woodruffe, and R. Murray, Problem solving in schizophrenia: a specific deficit in planning ability, Schizophrenia Research, vol.14, issue.3, pp.235-281, 1995.
DOI : 10.1016/0920-9964(94)00044-9

C. Muguruza, M. Lehtonen, N. Aaltonen, B. Morentin, J. Meana et al., Quantification of endocannabinoids in postmortem brain of schizophrenic subjects, Schizophrenia Research, vol.148, issue.1-3, pp.145-50, 2013.
DOI : 10.1016/j.schres.2013.06.013

D. Nathaniel-james, R. Brown, and M. Ron, Memory impairment in schizophrenia: Its' relationship to executive function, Schizophrenia Research, vol.21, issue.2, pp.85-96, 1996.
DOI : 10.1016/0920-9964(96)00038-2

K. Newell, C. Deng, and X. Huang, Increased cannabinoid receptor density in the posterior cingulate cortex in schizophrenia, Experimental Brain Research, vol.96, issue.2???3, pp.556-60, 2006.
DOI : 10.1007/s00221-006-0503-x

M. Nieuwenstein, A. Aleman, and E. De-haan, Relationship between symptom dimensions and neurocognitive functioning in schizophrenia: a meta-analysis of WCST and CPT studies, Journal of Psychiatric Research, vol.35, issue.2, pp.119-144, 2001.
DOI : 10.1016/S0022-3956(01)00014-0

D. Norman and T. Shallice, Attention to Action, Consciousness and Self- Regulation: Advances in Research and Theory IV, 1986.
DOI : 10.1007/978-1-4757-0629-1_1

T. Ohno-shosaku, Y. Hashimotodani, M. Ano, S. Takeda, H. Tsubokawa et al., Endocannabinoid signalling triggered by NMDA receptor-mediated calcium entry into rat hippocampal neurons, The Journal of Physiology, vol.26, issue.2, pp.407-425, 2007.
DOI : 10.1113/jphysiol.2007.137505

T. Ohno-shosaku and M. Kano, Endocannabinoid-mediated retrograde modulation of synaptic transmission, Current Opinion in Neurobiology, vol.29, pp.1-8, 2014.
DOI : 10.1016/j.conb.2014.03.017

Y. Okahisa, M. Kodama, M. Takaki, T. Inada, N. Uchimura et al., Association Study of Two Cannabinoid Receptor Genes, CNR1 and CNR2, with Methamphetamine Dependence, Current Neuropharmacology, vol.9, issue.1, pp.183-192, 2011.
DOI : 10.2174/157015911795017191

Y. Okamoto, J. Wang, J. Morishita, and N. Ueda, Biosynthetic Pathways of the Endocannabinoid Anandamide, Chemistry & Biodiversity, vol.103, issue.8, pp.1842-57, 2007.
DOI : 10.1002/cbdv.200790155

O. Onwuameze, K. Nam, E. Epping, T. Wassink, S. Ziebell et al., MAPK14 and CNR1 gene variant interactions: effects on brain volume deficits in schizophrenia patients with marijuana misuse, Psychological Medicine, vol.5, issue.03, pp.619-650, 2013.
DOI : 10.1001/jama.1994.03520220057031

J. Overall and D. Gorham, THE BRIEF PSYCHIATRIC RATING SCALE, Psychological Reports, vol.15, issue.3, pp.799-812, 1962.
DOI : 10.2466/pr0.1962.10.3.799

B. Palmer, S. Dawes, and R. Heaton, What Do We Know About Neuropsychological Aspects Of Schizophrenia?, Neuropsychology Review, vol.86, issue.2, pp.365-84, 2009.
DOI : 10.1007/s11065-009-9109-y

B. Palmer, R. Heaton, J. Paulsen, J. Kuck, D. Braff et al., Is it possible to be schizophrenic yet neuropsychologically normal?, Neuropsychology, vol.11, issue.3, pp.437-483, 1997.
DOI : 10.1037/0894-4105.11.3.437

S. Park and P. Holzman, Schizophrenics Show Spatial Working Memory Deficits, Archives of General Psychiatry, vol.49, issue.12, pp.975-82, 1992.
DOI : 10.1001/archpsyc.1992.01820120063009

S. Park, P. Holzman, and P. Goldman-rakic, Spatial Working Memory Deficits in the Relatives of Schizophrenic Patients, Archives of General Psychiatry, vol.52, issue.10, pp.821-829, 1995.
DOI : 10.1001/archpsyc.1995.03950220031007

A. Pélissier-alicot, Les cannabino??des de synth??se??: ??pid??miologie, modalit??s de consommations et effets cliniques, Toxicologie Analytique et Clinique, vol.27, issue.1, pp.33-40, 2015.
DOI : 10.1016/j.toxac.2014.10.002

M. Pelletier, A. Achim, A. Montoya, S. Lal, and M. Lepage, Cognitive and clinical moderators of recognition memory in schizophrenia: a meta-analysis, Schizophrenia Research, vol.74, issue.2-3, pp.233-52, 2005.
DOI : 10.1016/j.schres.2004.08.017

J. Perälä, J. Suvisaari, S. Saarni, K. Kuoppasalmi, E. Isometsä et al., Lifetime Prevalence of Psychotic and Bipolar I Disorders in a General Population, Archives of General Psychiatry, vol.64, issue.1, pp.19-28, 2007.
DOI : 10.1001/archpsyc.64.1.19

R. Pertwee, -tetrahydrocannabivarin, British Journal of Pharmacology, vol.22, issue.2, pp.199-215, 2008.
DOI : 10.1038/sj.bjp.0707442

F. Pijlman, S. Rigter, J. Hoek, H. Goldschmidt, and R. Niesink, Strong increase in total delta-THC in cannabis preparations sold in Dutch coffee shops, Addiction Biology, vol.249, issue.2, pp.171-80, 2005.
DOI : 10.1176/appi.ajp.161.3.501

J. Proietto, A. Rissanen, J. Harp, N. Erondu, Q. Yu et al., A clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: low-dose study, International Journal of Obesity, vol.32, issue.8, pp.1243-54, 2010.
DOI : 10.1210/jc.85.7.2402

A. Prouteau, Bilan cognitif dans la schizophrénie: spécificités Neuropsychologie clinique de la schizophrénie, pp.101-133, 2011.

A. Prouteau and H. Verdoux, 5. Les relations entre cognition et handicap psychique dans la schizophr??nie, Neuropsychologie clinique de la schizophrénie, pp.135-160, 2011.
DOI : 10.3917/dunod.prout.2011.01.0135

N. Puente, Y. Cui, O. Lassalle, M. Lafourcade, F. Georges et al., Polymodal activation of the endocannabinoid system in the extended amygdala, Nature Neuroscience, vol.11, issue.12, pp.1542-1549, 2011.
DOI : 10.2174/138161208783330790

URL : https://hal.archives-ouvertes.fr/hal-01160051

J. Ragland, R. Gur, J. Raz, L. Schroeder, C. Kohler et al., Effect of Schizophrenia on Frontotemporal Activity During Word Encoding and Recognition: A PET Cerebral Blood Flow Study, American Journal of Psychiatry, vol.158, issue.7, pp.1114-1139, 2001.
DOI : 10.1176/appi.ajp.158.7.1114

M. Raichle and A. Snyder, A default mode of brain function, Proceedings of the National Academy of Sciences, vol.98, issue.2, pp.1083-90, 2007.
DOI : 10.1073/pnas.98.2.676

M. Ranganathan, Cannabidiol Treatment of Cognitive Dysfunction in Schizophrenia

M. Riutort, C. Cuervo, J. Danion, C. Peretti, and P. Salamé, Reduced levels of specific autobiographical memories in schizophrenia, Psychiatry Research, vol.117, issue.1, pp.35-45, 2003.
DOI : 10.1016/S0165-1781(02)00317-7

L. Rizzo, J. Danion, M. Van-der-linden, and D. Grangé, Patients with schizophrenia remember that an event has occurred, but not when, The British Journal of Psychiatry, vol.168, issue.4, pp.427-458, 1996.
DOI : 10.1192/bjp.168.4.427

J. Rolland, C. Quiles, L. Mémoire, and L. Métamémoire, Contribution à L'analyse et L'évaluation de Ces Concepts Dans La Schizophrénie

B. Rund, Is schizophrenia a neurodegenerative disorder?, Nordic Journal of Psychiatry, vol.8, issue.12, pp.196-201, 2009.
DOI : 10.1080/08039480902767286

P. Salamé, F. Burglen, and J. Danion, Differential disruptions of working memory components in schizophrenia in an object???location binding task using the suppression paradigm, Journal of the International Neuropsychological Society, vol.153, issue.04, pp.510-518, 2006.
DOI : 10.1016/0001-6918(90)90066-O

P. Salamé, J. Danion, S. Peretti, and C. Cuervo, The state of functioning of working memory in schizophrenia, Schizophrenia Research, vol.30, issue.1, pp.11-29, 1998.
DOI : 10.1016/S0920-9964(97)00107-2

M. Saoud, T. Amato, C. Gutknecht, P. Triboulet, J. Bertaud et al., Neuropsychological Deficit in Siblings Discordant for Schizophrenia, Schizophrenia Bulletin, vol.26, issue.4, pp.893-902, 2000.
DOI : 10.1093/oxfordjournals.schbul.a033503

J. Schacht, K. Hutchison, and F. Filbey, Associations between Cannabinoid Receptor-1 (CNR1) Variation and Hippocampus and Amygdala Volumes in Heavy Cannabis Users, Neuropsychopharmacology, vol.9, issue.11, pp.2368-76, 2012.
DOI : 10.1038/npp.2012.92

J. Schaefer, E. Giangrande, D. Weinberger, and D. Dickinson, The global cognitive impairment in schizophrenia: Consistent over decades and around the world, Schizophrenia Research, vol.150, issue.1, pp.42-50, 2013.
DOI : 10.1016/j.schres.2013.07.009

C. Schubart, I. Sommer, P. Fusar-poli, L. De-witte, R. Kahn et al., Cannabidiol as a potential treatment for psychosis, European Neuropsychopharmacology, vol.24, issue.1, pp.51-64, 2014.
DOI : 10.1016/j.euroneuro.2013.11.002

C. Schubart, I. Sommer, W. Van-gastel, R. Goetgebuer, R. Kahn et al., Cannabis with high cannabidiol content is associated with fewer psychotic experiences, Schizophrenia Research, vol.130, issue.1-3, pp.216-237, 2011.
DOI : 10.1016/j.schres.2011.04.017

F. Schultze-lutter, J. Addington, S. Rurhmann, . Schizophrenia-proneness, and . Instrument, Adult Version (SPI-A), Giovanni Fioriti Editore, p.97, 2007.

J. Seifert, S. Ossege, H. Emrich, U. Schneider, and M. Stuhrmann, No association of CNR1 gene variations with susceptibility to schizophrenia, Neuroscience Letters, vol.426, issue.1, pp.29-33, 2007.
DOI : 10.1016/j.neulet.2007.08.008

D. Semple, F. Ramsden, and A. Mcintosh, Reduced binocular depth inversion in regular cannabis users, Pharmacology Biochemistry and Behavior, vol.75, issue.4, pp.789-93, 2003.
DOI : 10.1016/S0091-3057(03)00140-0

D. Sheehan, Y. Lecrubier, K. Sheehan, P. Amorim, J. Janavs et al., The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10, J Clin Psychiatry, vol.59, issue.20, pp.22-33, 1998.

H. Silver, P. Feldman, W. Bilker, and R. Gur, Working Memory Deficit as a Core Neuropsychological Dysfunction in Schizophrenia, American Journal of Psychiatry, vol.160, issue.10, pp.1809-1825, 2003.
DOI : 10.1176/appi.ajp.160.10.1809

L. Sim-selley and B. Martin, Effect of Chronic Administration of R-(+)-[2,3-Dihydro- 5-Methyl-3-[(morpholinyl)methyl]pyrrolo

. Naphthalenyl-)-methanone-mesylate, 212-2) or delta(9)-Tetrahydrocannabinol on Cannabinoid Receptor Adaptation in Mice, J Pharmacol Exp Ther, vol.55, issue.303, pp.36-44, 2002.

D. Smart, M. Gunthorpe, J. Jerman, S. Nasir, J. Gray et al., The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1), British Journal of Pharmacology, vol.400, issue.2, pp.227-257, 2000.
DOI : 10.1038/sj.bjp.0703050

N. Solowij and P. Michie, Cannabis and Cognitive Dysfunction, J Psychiatry Neurosci, vol.32, pp.30-52, 2007.

. Stahl, Stahl's Essential Psychopharmacology, 2013.

P. Suárez-pinilla, R. Roiz-santiañez, V. Ortiz-garcía-de-la-foz, P. Guest, R. Ayesa-arriola et al., Brain structural and clinical changes after first episode psychosis: Focus on cannabinoid receptor 1 polymorphisms, Psychiatry Research: Neuroimaging, vol.233, issue.2, pp.112-121, 2015.
DOI : 10.1016/j.pscychresns.2015.05.005

A. Tanimura, M. Uchigashima, M. Yamazaki, N. Uesaka, T. Mikuni et al., Synapse type-independent degradation of the endocannabinoid 2-arachidonoylglycerol after retrograde synaptic suppression, Proceedings of the National Academy of Sciences, vol.109, issue.30, pp.12195-200, 2012.
DOI : 10.1073/pnas.1204404109

P. Thomas, Les Antipsychotiques : Les Médicaments Psychotropes, 2013.

A. Tiwari, C. Zai, O. Likhodi, A. Voineskos, H. Meltzer et al., Association study of Cannabinoid receptor 1 (CNR1) gene in tardive dyskinesia, The Pharmacogenomics Journal, vol.107, issue.3, pp.260-266, 2012.
DOI : 10.1038/tpj.2010.93

D. Tong, S. He, L. Wang, J. L. Si, P. Cheng et al., Association of Single-Nucleotide Polymorphisms in the Cannabinoid Receptor 2 Gene with Schizophrenia in the Han Chinese Population, Journal of Molecular Neuroscience, vol.4, issue.1, pp.454-60, 2013.
DOI : 10.1007/s12031-013-0062-0

E. Tulving, L. Squire, N. Weinberger, G. Lynch, and J. Mcgauch, Concepts of human memory Memory: Organization and locus of change, pp.3-32, 1991.

E. Tulving, W. Donaldson, and G. H. Bower, Organization of memory, 1972.

E. Tzavara, D. Li, L. Moutsimilli, T. Bisogno, D. Marzo et al., Endocannabinoids Activate Transient Receptor Potential Vanilloid 1 Receptors to Reduce Hyperdopaminergia-Related Hyperactivity: Therapeutic Implications, Biological Psychiatry, vol.59, issue.6, pp.508-523, 2006.
DOI : 10.1016/j.biopsych.2005.08.019

H. Ujike, M. Takaki, K. Nakata, Y. Tanaka, T. Takeda et al., CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia, Molecular Psychiatry, vol.7, issue.5, pp.515-523, 2002.
DOI : 10.1038/sj.mp.4001029

T. Van-raalten, Practice and the Dynamic Nature of Working Memory, The Automatic Brain, vol.3, pp.47-79, 2009.

S. Vandevoorde and M. Lambert, Gros Plan Sur Les Endocannabinoïdes, de Nouveaux Agents Thérapeutiques Chimie nouvelle, pp.102-105, 2004.

L. Venance, R. Maldonado, and O. Manzoni, Le syst??me endocannabino??de central, m??decine/sciences, vol.20, issue.1, pp.45-53, 2004.
DOI : 10.1051/medsci/200420145

P. Vianin, Rem??diation cognitive de??la??schizophr??nie. Pr??sentation du??programme RECOS, Annales M??dico-psychologiques, revue psychiatrique, vol.165, issue.3, pp.200-205, 2007.
DOI : 10.1016/j.amp.2007.01.008

P. Vidailhet and C. Ch, M??moire, m??moires : l???exploration de la m??moire autobiographique dans la schizophr??nie, L'Enc??phale, vol.33, issue.3, pp.365-373, 2007.
DOI : 10.1016/S0013-7006(07)74582-7

D. Vigano, C. Guidali, S. Petrosino, N. Realini, T. Rubino et al., Involvement of the endocannabinoid system in phencyclidine-induced cognitive deficits modelling schizophrenia, The International Journal of Neuropsychopharmacology, vol.12, issue.05, pp.599-614, 2009.
DOI : 10.1017/S1461145708009371

A. Vita, G. Deste, S. Barlati, D. Peri, L. Giambra et al., Interview-based assessment of cognition in schizophrenia: Applicability of the Schizophrenia Cognition Rating Scale (SCoRS) in different phases of illness and settings of care, Schizophrenia Research, vol.146, issue.1-3, pp.217-240, 2013.
DOI : 10.1016/j.schres.2013.02.035

Z. Warraich and J. Kleim, Neural Plasticity: The Biological Substrate For Neurorehabilitation, PM&R, vol.2, issue.12, pp.208-227, 2010.
DOI : 10.1016/j.pmrj.2010.10.016

S. Whitfield-gabrieli and J. Ford, Default Mode Network Activity and Connectivity in Psychopathology, Annual Review of Clinical Psychology, vol.8, issue.1, pp.49-76, 2012.
DOI : 10.1146/annurev-clinpsy-032511-143049

R. Wilson and R. Nicoll, correction: Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses, Nature, vol.410, issue.6840, pp.588-592, 2001.
DOI : 10.1038/35082121

K. Woodberry, A. Giuliano, and L. Seidman, Premorbid IQ in Schizophrenia: A Meta-Analytic Review, American Journal of Psychiatry, vol.165, issue.5, pp.579-87, 2008.
DOI : 10.1176/appi.ajp.2008.07081242

S. Woods, Chlorpromazine Equivalent Doses for the Newer Atypical Antipsychotics, The Journal of Clinical Psychiatry, vol.64, issue.6, pp.663-670, 2003.
DOI : 10.4088/JCP.v64n0607

T. Younts, V. Chevaleyre, and P. Castillo, CA1 Pyramidal Cell Theta-Burst Firing Triggers Endocannabinoid-Mediated Long-Term Depression at Both Somatic and Dendritic Inhibitory Synapses, Journal of Neuroscience, vol.33, issue.34, pp.13743-57, 2013.
DOI : 10.1523/JNEUROSCI.0817-13.2013

S. Zammit, M. Owen, J. Evans, J. Heron, and G. Lewis, Cannabis, COMT and psychotic experiences, The British Journal of Psychiatry, vol.199, issue.5, pp.380-385, 2011.
DOI : 10.1192/bjp.bp.111.091421

K. Zavitsanou, T. Garrick, and X. Huang, Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia, Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol.28, issue.2, pp.355-60, 2004.
DOI : 10.1016/j.pnpbp.2003.11.005

A. Zhang, H. Ishiguro, T. Ohtsuki, J. Hess, F. Carillo et al., Human cannabinoid receptor 1: 5??? exons, candidate regulatory regions, polymorphisms, haplotypes and association with polysubstance abuse, Molecular Psychiatry, vol.9, issue.10, pp.916-931, 2004.
DOI : 10.1038/sj.mp.4001560

A. Zuardi, J. Crippa, J. Hallak, S. Bhattacharyya, Z. Atakan et al., A Critical Review of the Antipsychotic Effects of Cannabidiol: 30 Years of a Translational Investigation, Current Pharmaceutical Design, vol.18, issue.32, pp.5131-5171, 2012.
DOI : 10.2174/138161212802884681

A. Zuardi, J. Crippa, J. Hallak, J. Pinto, M. Chagas et al., Cannabidiol for the treatment of psychosis in Parkinson's disease, Journal of Psychopharmacology, vol.23, issue.8, pp.979-83, 2009.
DOI : 10.1177/0269881108096519

A. Zuardi, J. Hallak, S. Dursun, S. Morais, R. Sanches et al., Cannabidiol monotherapy for treatment-resistant schizophrenia, Journal of Psychopharmacology, vol.16, issue.212, pp.683-689, 2006.
DOI : 10.1177/0269881106060967

A. Zuardi, S. Morais, F. Guimarães, and R. Mechoulam, Antipsychotic Effect of Cannabidiol, J Clin Psychiatry, vol.56, pp.485-491, 1995.